Artyc PBC

Artyc PBC is a technology company.

Active

Updated: Mar 21, 2026 ·

About

Artyc PBC develops battery-powered, reusable shipping solutions for precision cold chain transport, replacing traditional dry ice and gel packs. Its Medstow Micro and Medstow 5L-Intercampus products provide accurate temperature control for sensitive medical and pharmaceutical materials. These smart shippers integrate with a cloud platform for real-time monitoring of temperature, location, and handling, ensuring visibility and compliant audit trails.

Founded in 2021, Artyc PBC originated from co-founder and CEO Hannah Sieber, an entrepreneur with a clean tech and electrification background. Sieber identified the inefficiencies and environmental drawbacks of conventional cold chain logistics, stating, "Dry ice is a relic." This insight propelled the company to pioneer sustainable, intelligent alternatives.

Artyc's solutions serve healthcare systems, clinical research, mobile health, and pharmaceutical companies, enabling reliable transport of biologics, patient samples, and investigational products. The company envisions establishing a reliable, sustainable, intelligent cold shipping infrastructure globally, reducing waste and safeguarding materials across the mid-to-last mile.

Recent News & Mentions

Jun 1, 2023FundingArtyc PBC - Series A

Financial History

Artyc PBC has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in June 2023.

Total Raised

$11.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Jun 1, 2023	$11.0M Series A		SOSV

Financial History

Artyc PBC has raised $11.0M across 1 funding round.

Total Raised

$11.0M

Valuation

N/A

Deep Dive

Artyc PBC is a climate‑tech company that builds reusable, battery‑powered IoT coolers and a software platform to provide precise temperature control, live tracking, and chain‑of‑custody for transporting temperature‑sensitive medical goods and specialty foods, with an initial focus on healthcare, clinical research, and decentralized care use cases[1][4]. Artyc’s products (e.g., Medstow Micro and Medstow 5L Intercampus) replace disposable cold‑chain methods like dry ice with programmable cooling, onboard sensors for GPS/temperature/lid openings/shock, and cloud monitoring for real‑time visibility and audit trails[2][5].

High‑Level Overview

Mission: Artyc positions itself as a purpose‑driven company aiming to modernize and decarbonize the cold chain so life‑saving medicines and diagnostics reliably reach patients while reducing waste and complexity in logistics[6][3].- Investment philosophy / Key sectors / Impact on startup ecosystem: (Not applicable — Artyc is a portfolio company / operating company rather than an investment firm). Instead, Artyc targets the healthcare, life‑sciences, clinical research, mobile health, and specialty food sectors with solutions for mid‑to‑last‑mile temperature‑sensitive transport[4][1]. Their impact on the ecosystem includes enabling decentralized clinical trials and at‑home specimen collection by providing compliant, auditable cold‑chain hardware + software that reduces reliance on single‑use consumables and dry ice[3][2].

Origin Story

Founding and location: Artyc was founded in 2021 and is based in Fremont, California[1].- Founders and emergence: Public materials identify Hannah Sieber as a co‑founder and CEO who has spoken publicly about replacing dry ice with intelligent reusable systems; Artyc’s first products (Medstow Micro) were designed to enable remote specimen collection and decentralized trials[3][2].- Early traction / pivotal moments: Artyc launched the Medstow Micro as an inaugural product and later introduced the Medstow 5L Intercampus for interfacility and at‑home workflows; the company was named a World Economic Forum Technology Pioneer in 2024, signaling external recognition of its potential impact[3][2].

Core Differentiators

Product + technical differentiators: Battery‑powered compressor cooling with programmable temperature setpoints and stabilization (±3°C claimed for Medstow 5L), plus reusable industrial designs that eliminate dry ice and single‑use packaging[5][2].- Observability & compliance: Onboard sensors (GPS, ambient temp, lid open, shock) and a cloud portal providing live monitoring, temperature history, battery usage, and chain‑of‑custody logs for regulatory and clinical workflows[2][5].- Sustainability & cost posture: Reusable platform aims to reduce consumable waste and procurement/reimbursement complexity compared with disposable cold‑chain methods[2][6].- Targeted workflows / product‑market fit: Purpose‑built for mid‑to‑last‑mile healthcare logistics — intra‑hospital transfers, decentralized clinical trial shipments, mobile health specimen transport, and specialty biologics shipping[4][5].

Role in the Broader Tech Landscape

Trends they ride: Decentralized clinical trials, growth of at‑home diagnostics and mobile health, and rising demand for resilient, low‑waste cold chains for biologics and mRNA therapies[3][4].- Timing: Increased distributed care and complex biologics create urgent demand for portable, auditable cold solutions; simultaneously, sustainability and supply‑chain resilience are high priorities for health systems and regulators[6][3].- Market forces in their favor: Rising volume of temperature‑sensitive biologics, regulatory emphasis on traceability/audit trails for clinical samples, and the operational pain/cost of dry ice and one‑time packaging[5][2].- Influence: By enabling reliable, monitored mid‑to‑last‑mile shipments, Artyc can accelerate adoption of decentralized diagnostics and trials and reduce losses from spoilage, thereby influencing procurement and logistics practices in healthcare and research[6][3].

Quick Take & Future Outlook

Near term: Expect expanded deployments of Medstow devices into hospital intercampus logistics and clinical research programs, further product iterations (size/temperature ranges), and deeper integrations between hardware telemetry and clinical/compliance software[2][4].- Medium term: If adoption scales, Artyc could become a category leader for reusable, connected cold‑chain hardware in healthcare, pressuring incumbents (dry‑ice suppliers, specialty shippers) and encouraging standards for device‑level auditability. Recognition such as WEF Technology Pioneer supports partnership and policy visibility[3].- Risks & considerations: Adoption depends on clinical validation, regulatory acceptance for specific sample types/temperatures, procurement cycles of health systems, and total cost of ownership versus existing methods[5][6].- Final thought: Artyc addresses a concrete operational and sustainability problem with an integrated hardware + software approach at a time when decentralized care and biologics demand better mid‑to‑last‑mile cold solutions, positioning the company to materially influence how sensitive medical materials are moved and monitored[2][3].

If you’d like, I can: produce a one‑page investor‑style summary, compare Artyc’s product specs to competitors, or compile press and technical references (device specs, regulatory guidance) to support due diligence.

Sources

Frequently Asked Questions

How much funding has Artyc PBC raised?

Artyc PBC has raised $11.0M in total across 1 funding round.

Who are Artyc PBC's investors?

Artyc PBC's investors include SOSV.

Frequently Asked Questions

How much funding has Artyc PBC raised?

Artyc PBC has raised $11.0M in total across 1 funding round.